MetrioPharm AG: MetrioPharm AG Publishes Annual Report for 2018
EQS Group-News: MetrioPharm AG / Key word(s): Annual Results/Annual Results
- Financing round D for 20 CHF was closed
- Phase II clinical trial successfully initiated
- Focus of the report: InflammAging
Zurich, May 16, 2019. MetrioPharm AG, a pharmaceutical development company, publishes its annual report for 2018.
Dr. Wolfgang Brysch, CEO of MetrioPahrm AG: "In the past fiscal year, we were able to decisively advance the development of our lead compound MP1032. In April, the Phase II clinical trial for the indication psoriasis started. Patient recruitment has now been completed to our satisfaction.
Patient acceptance is an important signal for us, it confirms us in expanding our development strategy: From autoimmune diseases to the constantly growing field of age-related chronic inflammatory diseases (InflammAging). The need for well-tolerated and safe therapies is still almost unmet.
With the 20 million CHF from the current financing round, we will be able to effectively drive this strategy forward."
For an introduction to the main topic of the annual report InflammAging, please visit the MetrioPharm Blog.
You can find the complete annual report as PDF here.
You can also order a printed copy.
MetrioPharm AG is a pharmaceutical development company developing drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. We hope to achieve a healthspan expansion for patients: We want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people.
MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.
MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.
For the first Phase II study with MP1032, the indication psoriasis was selected because this immune-induced inflammatory disease is regarded as a so-called »door-opener indication«. Successes in the treatment of psoriasis have already led to first indications of promise for use in other chronic inflammatory diseases, such as arthritis and multiple sclerosis.
This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm's assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm's control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly.
Head of Investor Relations & Corporate Communications
MetrioPharm Deutschland GmbH
Am Borsigturm 100
T +49 (0) 30 33 84 395 40
F +49 (0) 30 33 84 395 99
Document title: MetrioPharm Press Release 2018 Annual Report
End of Corporate News
|Phone:||+41 (44) 515 21 97|
|Fax:||+41 (44) 201 74 75|
|EQS News ID:||812437|
|End of News||EQS Group News Service|